The ANTARDHWANI platform is not a single-purpose device. It is a clinical foundation — extensible across the full spectrum of human health, from early childhood development to complex adult disease.
Early identification and therapeutic intervention for autism spectrum disorder is one of the most powerful predictors of positive long-term outcomes — yet reliable tools remain inaccessible to most of the world's families. The ANTARDHWANI platform is being designed to enable scalable, community-level ASD therapy at a cost and portability profile that existing tools cannot approach.
By enabling intervention during the critical early developmental window — before age three, when neuroplasticity is at its peak — the platform has the potential to transform outcomes for millions of children who would otherwise go undiagnosed for years.
Prenatal assessment and early therapeutic support for Down syndrome currently relies on invasive procedures carrying real procedural risk, or expensive non-invasive tests financially out of reach for most expectant families worldwide. The ANTARDHWANI platform enables safe, non-invasive prenatal and postnatal assessment using acoustic imaging and AI analysis.
The goal is to give every expectant parent — regardless of geography or income — access to the same quality of information that is currently available only to those in wealthy health systems, without the risk or cost of invasive chromosomal testing.
The ANTARDHWANI platform is not limited to diagnostics. The same acoustic technology that enables high-resolution imaging can be focused and directed to deliver therapeutic energy — without a single incision. Focused ultrasound therapy enables targeted tissue ablation and treatment of conditions that would otherwise require surgery.
Incisionless therapeutic applications eliminate surgical risk, reduce recovery time to near zero, and — critically — can be performed in settings without operating theaters or surgical teams. This is a step-change in how treatment is delivered, especially in resource-limited environments.
What makes ANTARDHWANI unique is not any single application — it is the fact that one platform can address all of them. A single device, in the hands of a single clinician, can assess neurodevelopmental markers, provide prenatal insights, and deliver therapeutic treatment. This convergence is unprecedented.
Population-level screening programs enabled by portability and low cost
AI-assisted identification of anomalies with real-time clinical guidance
Characterization and differentiation to inform confident clinical decisions
Focused therapeutic delivery — incisionless, targeted, and immediate